Overview

RO7200220 in Participants With Uveitic Macular Edema

Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of RO7200220 in participants with uveitic macular edema.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche